Characterization of the m6A-related lncRNA signature in predicting prognosis and immune response in patients with colon cancer.

Q2 Medicine
Journal of Buon Pub Date : 2021-09-01
Shujia Chen, Xiaofei Li, Lianyi Guo, Jiachen Zhang, Li Li, Xueqiu Wang, Yinghui Zhu, Jiwei Wang
{"title":"Characterization of the m6A-related lncRNA signature in predicting prognosis and immune response in patients with colon cancer.","authors":"Shujia Chen,&nbsp;Xiaofei Li,&nbsp;Lianyi Guo,&nbsp;Jiachen Zhang,&nbsp;Li Li,&nbsp;Xueqiu Wang,&nbsp;Yinghui Zhu,&nbsp;Jiwei Wang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Colon adenocarcinoma (COAD) is globally one of the most frequently occurring malignant tumors. The patients' 5-year survival rate with colon cancer was poor. There is a usual form of mRNA modification called N6-methyl adenosine (m6A). It is adjusted by the m6A RNA methylation modulator. Nevertheless, few studies of COAD can fully discuss m6A-related lncRNAs' prognostic function.</p><p><strong>Methods: </strong>From The Cancer Genome Atlas (TCGA) database, this study of COAD samples discussed 23 m6A regulator-related lncRNAs systemically. 2 m6A patterns with various clinical results were recognized, and a remarkable correlation between various m6A clusters and tumor immune microenvironment was discovered.</p><p><strong>Results: </strong>According to prognostic analysis, cluster1 had a higher immune checkpoint programmed death-ligand 1 (PD-L1) expression and a better prognosis. A 6 m6A-related lncRNAs model was constructed through least absolute shrinkage and selection operator (LASSO), univariate, multivariate Cox regression and stratified analysis. The outcomes reported that compared with the low-risk group, high-risk groups that were based on model closely were related to poor overall survival (OS). The study ensured a risk model consisting of 6 m6A-related lncRNAs as independent prognosis predictors. For the expression differences between the two groups, Genomes Pathway Analysis, Kyoto Encyclopedia of Genes (KEGG) and Gene Ontology (GO) biological process analyses were conducted. In addition, on the basis of full analysis of OS, a nomogram based on gender, age, lncRNA feature and the stage was constructed. One year, two years, and three years are the periods when the calibration chart performed best.</p><p><strong>Conclusions: </strong>The outcomes of the study confirmed the underlying function of m6A-related lncRNAs and offered fresh perspectives to COAD prognosis.</p>","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Colon adenocarcinoma (COAD) is globally one of the most frequently occurring malignant tumors. The patients' 5-year survival rate with colon cancer was poor. There is a usual form of mRNA modification called N6-methyl adenosine (m6A). It is adjusted by the m6A RNA methylation modulator. Nevertheless, few studies of COAD can fully discuss m6A-related lncRNAs' prognostic function.

Methods: From The Cancer Genome Atlas (TCGA) database, this study of COAD samples discussed 23 m6A regulator-related lncRNAs systemically. 2 m6A patterns with various clinical results were recognized, and a remarkable correlation between various m6A clusters and tumor immune microenvironment was discovered.

Results: According to prognostic analysis, cluster1 had a higher immune checkpoint programmed death-ligand 1 (PD-L1) expression and a better prognosis. A 6 m6A-related lncRNAs model was constructed through least absolute shrinkage and selection operator (LASSO), univariate, multivariate Cox regression and stratified analysis. The outcomes reported that compared with the low-risk group, high-risk groups that were based on model closely were related to poor overall survival (OS). The study ensured a risk model consisting of 6 m6A-related lncRNAs as independent prognosis predictors. For the expression differences between the two groups, Genomes Pathway Analysis, Kyoto Encyclopedia of Genes (KEGG) and Gene Ontology (GO) biological process analyses were conducted. In addition, on the basis of full analysis of OS, a nomogram based on gender, age, lncRNA feature and the stage was constructed. One year, two years, and three years are the periods when the calibration chart performed best.

Conclusions: The outcomes of the study confirmed the underlying function of m6A-related lncRNAs and offered fresh perspectives to COAD prognosis.

m6a相关lncRNA在预测结肠癌患者预后和免疫反应中的特征
目的:结肠腺癌(COAD)是全球最常见的恶性肿瘤之一。结肠癌患者的5年生存率较低。有一种常见的mRNA修饰形式叫做n6 -甲基腺苷(m6A)。它由m6A RNA甲基化调节剂调节。然而,很少有关于COAD的研究能够充分讨论m6a相关lncrna的预后功能。方法:本研究从癌症基因组图谱(TCGA)数据库中,对COAD样本的23个m6A调控因子相关的lncrna进行了系统的讨论。识别出2种具有不同临床结果的m6A模式,发现各种m6A簇与肿瘤免疫微环境之间存在显著相关性。结果:根据预后分析,cluster1具有较高的免疫检查点程序性死亡配体1 (PD-L1)表达,预后较好。通过最小绝对收缩和选择算子(LASSO)、单因素、多因素Cox回归和分层分析,构建6 m6a相关lncRNAs模型。结果报告:与低风险组相比,基于模型的高风险组与较差的总生存期(OS)相关。该研究确保了由6个m6a相关lncrna组成的风险模型作为独立的预后预测因子。对于两组的表达差异,分别进行了基因组途径分析、京都基因百科全书(KEGG)和基因本体(GO)生物过程分析。此外,在充分分析OS的基础上,构建了基于性别、年龄、lncRNA特征和阶段的nomogram。1年、2年和3年是校准图表现最好的时期。结论:本研究结果证实了m6a相关lncrna的潜在功能,并为COAD的预后提供了新的视角。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Buon
Journal of Buon 医学-肿瘤学
自引率
0.00%
发文量
0
审稿时长
4-8 weeks
期刊介绍: JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信